Omnicell (OMCL) PT Lowered to $55 at Piper Sandler Despite Guide Raise

Piper Sandler analyst Jessica Tassan lowered the price target on Omnicell (NASDAQ: OMCL) to $55.00 (from $57.00) while maintaining a Overweight rating.

The analyst commented: "CY25 Guide Rises on Strong 2Q25 Results & Solid Demand; OMCL raised CY25 guidance on 2Q25 strength across both segments and a dynamic China tariff situation. We update our product gross margin forecast for 2H25 and CY26 to reflect management's latest commentary and the expectation that mitigation efforts eliminate effectively all China tariff impact by 4Q26. We reiterate our Overweight rating; PT to $55 on an unchanged 20x multiple of CY26E adjusted EBITDA."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Aurora Spine settles patent dispute, secures $600K insider loan